DDInter150 DDInter1602
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.
Azathioprine {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Risankizumab
Azathioprine {u} (Compound) downregulates {v} (Gene) MCM3
MCM3 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Azathioprine {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is downregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Risankizumab
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Azathioprine {u} (Compound) upregulates {v} (Gene) ABHD4
ABHD4 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Risankizumab
Azathioprine {u} (Compound) causes {v} (Side Effect) Non-Hodgkin's lymphoma
Non-Hodgkin's lymphoma {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Azathioprine {u} (Compound) causes {v} (Side Effect) Non-Hodgkin's lymphoma
Non-Hodgkin's lymphoma {u} (Side Effect) is caused by {v} (Compound) Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Risankizumab
Azathioprine {u} (Compound) treats {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Risankizumab
Azathioprine (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Azathioprine (Compound) downregulates MCM3 (Gene) and MCM3 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Azathioprine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is downregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Risankizumab
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Azathioprine (Compound) upregulates ABHD4 (Gene) and ABHD4 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Risankizumab
Azathioprine (Compound) causes Non-Hodgkin's lymphoma (Side Effect) and Non-Hodgkin's lymphoma (Side Effect) is caused by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Azathioprine (Compound) causes Non-Hodgkin's lymphoma (Side Effect) and Non-Hodgkin's lymphoma (Side Effect) is caused by Fingolimod (Compound) and Fingolimod may lead to a major life threatening interaction when taken with Risankizumab
Azathioprine (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Risankizumab